Business
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
-REGENXBIO AAV Therapeutics pipeline to be discussed by management and external experts -Focus on programs for Wet AMD, Diabetic Retinopathy, and Duchenne
About this update from Regenxbio Inc.
[{"type":"text","content":"-REGENXBIO AAV Therapeutics pipeline to be discussed by management and external experts\n-Focus on programs for Wet AMD, Diabetic Retinopathy, and Duchenne Muscular Dystrophy\nROCKVILLE, Md., June 27, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a virtual investor day on July 11, 2023. During the event, members of REGENXBIO's management team and external experts will provide an update to the investment community on the Company's pipeline, with a focus on programs with expected interim clinical trial data to be presented in the second half of 2023.\nThe program will include presentations of the ABBV-RGX-314 eye care program, including plans for interim data updates from the Phase II AAVIATE® and ALTITUDE® trials. It will also include an overview of RGX-202, an investigational one-time gene therapy utilizing a novel microdystrophin construct for the treatment of Duchenne Muscular Dystrophy (Duchenne), including the expected plans for interim data updates from the Phase I/II AFFINITY DUCHENNE™ trial.\nIn addition, management will highlight the features and performance of the fully operational REGENXBIO Manufacturing Innovation Center, which is designed to support commercial readiness. This facility is producing GMP lots to support the ABBV-RGX-314 and RGX-202 programs using the NAVXpress™ platform process, which has demonstrated the ability to increase product purity and yield.\nA live question and answer session will follow the program.\nThe event will feature the following external experts:\nGeorge Dickson, world-class researcher in Duchenne and Professor of Molecular Cell Biology at Royal Holloway – University of London.Dr. Peter Kaiser, MD FASRS, Chair for Ophthalmology Research and a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine.Dr. Veeral Sheth, MD, MBA, FACS, FASRS, board-certified vitreoretinal surgeon and Partner at University Retina and Macula Associates in Chicago.The virtual event will take place on Tuesday, July 11, 2023 at 8:30 a.m. Eastern Time. The webcast and slides of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.\nAbout REGENXBIO Inc. \...